Accuracy of faecal occult blood test and Helicobacter pylori stool antigen test for detection of upper gastrointestinal lesions

BMJ Open

Volumn 3, Issue 10, 2013, Pages

  Lee, Yi Chia ^a,b   Chiu, Han Mo ^a,b   Chiang, Tsung Hsien ^a,c   Yen, Amy Ming Fang ^d   Chiu, Sherry Yueh Hsia ^e   Chen, Sam Li Sheng ^d   Fann, Jean Ching Yuan ^f   Yeh, Yen Po ^g   Liao, Chao Sheng ^h   Hu, Tsung Hui ⁱ   Tu, Chia Hung ^a   Tseng, Ping Huei ^a   Chen, Chien Chuan ^a   Chen, Mei Jyh ^a,c   Liou, Jyh Ming ^a,b   Liao, Wei Chih ^a,b   Lai, Yo Ping ^a   Wang, Chen Ping ^c   Ko, Jenq Yuh ^c   Wang, Hsiu Po ^a   Chiang, Hung ^j   Lin, Jaw Town ^a,h,k,l   Chen, Hsiu Hsi ^b   Wu, Ming Shiang ^a   more..

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e CHANG GUNG UNIVERSITY   (Taiwan)

^f KAINAN UNIVERSITY   (Taiwan)

^g Changhua County Public Health Bureau   (Taiwan)

^h SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

ⁱ CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^j Taipei Institute of Pathology   (Taiwan)

^k FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^l E DA HOSPITAL   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; GUAIAC;

ADULT; AGED; ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM INJURY; ESOPHAGOGASTRODUODENOSCOPY; FECES ANALYSIS; FEMALE; HELICOBACTER PYLORI; HELICOBACTER PYLORI STOOL ANTIGEN TEST; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; UPPER GASTROINTESTINAL LESION; UPPER GASTROINTESTINAL TRACT;

EID: 84887933876     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003989     Document Type: Article

References (53)

1. Ferlay J, Shin HR, Bray F, et al. Globocan 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer, 2010. http://globocan.iarc.fr (accessed 10 Oct 2012).
2. Bloom DE, Cafiero ET, Jané-Llopis E, et al. The Global Economic Burden of noncommunicable diseases. Geneva: World Economic Forum, 2011.
3. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009;59:27-41. Review.
4. Chen TH, Chiu YH, Luh DL, et al. Taiwan Community-Based Integrated Screening Group. Community-based multiple screening model: design, implementation, and analysis of 42,387 participants. Cancer 2004;100:1734-43. (Pubitemid 38456353)
5. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013;369:1106-14.
6. Chiang TH, Lee YC, Tu CH, et al. Performance of the immunochemical fecal occult blood test in predicting lesions in the lower gastrointestinal tract. CMAJ 2011;183:1474-81.
7. Rockey DC. Occult gastrointestinal bleeding. N Engl J Med 1999;341:38-46. Review. (Pubitemid 29293719)
8. Rockey DC, Auslander A, Greenberg PD. Detection of upper gastrointestinal blood with fecal occult blood tests. Am J Gastroenterol 1999;94:344-50. (Pubitemid 29084651)
9. Young GP, Bosch LJ. Fecal tests: from blood to molecular markers. Curr Colorectal Cancer Rep 2011;7:62-70.
10. Malfertheiner P, Megraud F, O'Morain CA, et al. European Helicobacter Study Group. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report. Gut 2012;61:646-64.
11. Bosman FT, Carneiro F, Hruban RH, et al. eds. WHO classification of tumours of the digestive system. Lyon: IARC, 2010.
12. Cancer Control and Prevention. Health Promotion Administration, Ministry of Health and Welfare. Taiwan, ROC. http://www.hpa.gov.tw/BHPNet/English/Index. aspx (accessed 25 Jul 2013).
13. Lee YC, Tseng PH, Liou JM, et al. Performance of a one-step fecal sample-based test for diagnosis of Helicobacter pylori infection in primary care and mass screening settings. J Formos Med Assoc doi:10.1016/j.jfma.2012.05.014. [Epub ahead of print].
14. Chen LS, Liao CS, Chang SH, et al. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (kcis 16). J Med Screen 2007;14:191-9.
15. Chiu HM, Lin JT, Lee YC, et al. Different bowel preparation schedule leads to different diagnostic yield of proximal and nonpolypoid colorectal neoplasm at screening colonoscopy in average-risk population. Dis Colon Rectum 2011;54:1570-7.
16. Rockey DC, Koch J, Cello JP, et al. Relative frequency of upper gastrointestinal and colonic lesions in patients with positive fecal occult-blood tests. N Engl J Med 1998;339:153-9. (Pubitemid 28328479)
17. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-80. (Pubitemid 29333764)
18. Tajiri T, Yoshida H, Obara K, et al. General rules for recording endoscopic findings of esophagogastric varices (2nd edition). Dig Endosc 2010;22:1-9.
19. Benson VS, Atkin WS, Green J, et al. International colorectal cancer screening network. Toward standardizing and reporting colorectal cancer screening indicators on an international level: the international colorectal cancer screening network. Int J Cancer 2012;130:2961-73.
20. Allison JE, Tekawa IS, Ransom LJ, et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155-9. (Pubitemid 26017953)
21. Greenberg PD, Bertario L, Gnauck R, et al. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol 2000;95:1331-8. (Pubitemid 30263533)
22. Edge SB, Byrd DR, Carducci MA, et al. eds. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 7th edn. New York: Springer, 2009.
23. Altman DG, Bland JM. Diagnostic tests 2: predictive values. BMJ 1994;309:102. (Pubitemid 24216428)
24. Vecchio TJ. Predictive value of a single diagnostic test in unselected populations. N Engl J Med 1966;274:1171-3.
25. Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol 2006;101:1921-30. (Pubitemid 44166605)
26. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009;361:170-7. Review.
27. Tseng PH, Lee YC, Chiu HM, et al. Association of diabetes and HbA1c levels with gastrointestinal manifestations. Diabetes Care 2012;35:1053-60.
28. Chiu HM, Lee YC, Tu CH, et al. Association between early-stage colon neoplasms and false-negative results from the fecal immunochemical test. Clin Gastroenterol Hepatol 2013;11:832-8.
29. Cancer Statistics. Taiwan Cancer Registry. http://crs.cph.ntu.edu.tw/ main.php (accessed 21 Nov 2012).
30. Allard J, Cosby R, Del Giudice ME, et al. Gastroscopy following a positive fecal occult blood test and negative colonoscopy: systematic review and guideline. Can J Gastroenterol 2010;24:113-20.
31. Thomas WM, Hardcastle JD. Role of upper gastrointestinal investigation in a screening study for colorectal neoplasia. Gut 1990;31:1294-7.
32. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607-15.
33. Lee YC, Lin JT, Wu HM, et al. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev 2007;16:875-85.
34. Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 2013;62:676-82.
35. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011;378:507-14.
36. Liou JM, Chen CC, Chen MJ, et al. Taiwan Helicobacter Consortium. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013;381:205-13.
37. Shiotani A, Cen P, Graham DY. Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol 2013. doi:pii:S1044-579X(13)00066-7. 10.1016/j.semcancer.2013.07.004. [Epub ahead of print].
38. Wong BC, Lam SK, Wong WM, et al.; China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94. (Pubitemid 38082812)
39. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73. (Pubitemid 32240315)
40. Aro P, Storskrubb T, Ronkainen J, et al. Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol 2006;163:1025-34. (Pubitemid 43987595)
41. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009;29:938-46.
42. Wang AY, Peura DA. The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world. Gastrointest Endosc Clin N Am 2011;21:613-35.
43. World Gastroenterology Organisation. World Gastroenterology Organisation Global Guideline: Helicobacter pylori in developing countries. J Clin Gastroenterol 2011;45:383-8.
44. Musumba C, Jorgensen A, Sutton L, et al. The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. Aliment Pharmacol Ther 2012;36:48-56.
45. Sánchez-Delgado J, Gené E, Suárez D, et al. Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression. Am J Gastroenterol 2011;106:398-405.
46. Goss PE, Lee BL, Badovinac-Crnjevic T, et al. Planning cancer control in Latin America and the Caribbean. Lancet Oncol 2013;14:391-436.
47. Dutta AK, Chacko A, Balekuduru A, et al. Time trends in epidemiology of peptic ulcer disease in India over two decades. Indian J Gastroenterol 2012;31:111-15.
48. Agha A, Graham DY. Evidence-based examination of the African enigma in relation to Helicobacter pylori infection. Scand J Gastroenterol 2005;40:523-9. (Pubitemid 40676245)
49. Annibale B, Capurso G, Baccini F, et al. Role of small bowel investigation in iron deficiency anaemia after negative endoscopic/histologic evaluation of the upper and lower gastrointestinal tract. Dig Liver Dis 2003;35:784-7. (Pubitemid 41070508)
50. Harewood GC, McConnell JP, Harrington JJ, et al. Detection of occult upper gastrointestinal tract bleeding: performance differences in fecal occult blood tests. Mayo Clin Proc 2002;77:23-8. (Pubitemid 34049607)
51. Nagasaka T, Tanaka N, Cullings HM, et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst 2009;101:1244-58.
52. Ahlquist DA. Next-generation stool DNA testing: expanding the scope. Gastroenterology 2009;136:2068-73.
53. Asaka M, Kato M, Graham DY. Strategy for eliminating gastric cancer in Japan. Helicobacter 2010;15:486-90.